Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

CFO and COO

Exec. Vice President, Research

Chief Financial Officer

Chief Scientific Officer

Chief Medical Officer

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. The company is developing antibody-based therapeutics with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcoholic hepatitis and asialoglycoprotein receptor 1; and SZN-1326, a bi-specific antibody, which is in Phase 1b clinical trial for the treatment of moderate to severe inflammatory bowel disease, Frizzled, and LRP receptors. The company also develops SZN-413, a Fzd4 targeted bi-specific antibody, which is in preclinical stage for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. was founded in 2015 and is based in South San Francisco, California.

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-04-04	Premium	bought	Premium	Premium	Premium	-
2024-04-04	Premium	bought	Premium	Premium	Premium	-
2024-04-04	Premium	bought	Premium	Premium	Premium	-
2024-04-04	Premium	bought	Premium	Premium	Premium	-
2024-04-04	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2024-04-04	Premium	bought	Premium	Premium	Premium	CFO and COO
2023-12-15	Premium	acquired	Premium	Premium	Premium	Exec. Vice President, Research
2023-12-15	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2023-12-15	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-06-15	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2023-06-15	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2023-06-15	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-12-15	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2022-12-15	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2022-12-15	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2022-12-15	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2022-12-14	Premium	sold	Premium	Premium	Premium	-
2022-12-14	Premium	sold	Premium	Premium	Premium	-
2022-12-14	Premium	sold	Premium	Premium	Premium	-
2022-12-14	Premium	sold	Premium	Premium	Premium	-
2021-08-11	Premium	back to issuer	Premium	Premium	Premium	-

SRZN - Surrozen, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for SRZN